Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MYGN
SELLMyriad Genetics, Inc. · Healthcare · United States · $530M · Avg Vol: $7M/d
COMPANY DESCRIPTION
Myriad Genetics, Inc. is a leading genetic testing and precision medicine company focused on developing and commercializing tests for cancer risk assessment, prognosis, and treatment selection. Its competitive advantage lies in a robust portfolio of proprietary diagnostic tests, extensive genomic database, and strong intellectual property, making it a pioneer in personalized healthcare.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 678.4M | 753.2M | 837.6M | 824.5M | 6.7% | 557.0M | 863.6M | 915.8M | 5.4% |
| EPS | -1.39 | -3.18 | -1.41 | -3.95 | — | -4.13 | — | — | — |
| Shares | 81.2M | 89.9M | 91.3M | 93.5M | +15.1% | 94.4M | — | — | — |
| Debt | 145.0M | 152.1M | 140.3M | 209.8M | 13.1% | — | — | — | — |
| Equity | 885.8M | 783.2M | 701.1M | 368.0M | -25.4% | — | — | — | — |
| Op CF | -106.3M | -110.9M | -8.7M | 1.8M | — | -26.2M | — | — | — |
| Inv CF | -77.5M | 31.9M | -11.9M | -27.4M | — | — | — | — | — |
| Fin CF | -8.0M | 152.9M | -7.4M | 64.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MYGN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MYGN | Myriad Genetics, Inc.(you) | $530M | 35 | SELL |
| FLGT | Fulgent Genetics, Inc. | $559M | 27 | SELL |
| OPK | OPKO Health, Inc. | $921M | 35 | HOLD |
| BDSX | Biodesix, Inc. | $228M | 38 | HOLD |
| CSTL | Castle Biosciences, Inc. | $749M | 19 | STRONG SELL |
| PSNL | Personalis, Inc. | $1.3B | 24 | SELL |
| NEO | NeoGenomics, Inc. | $1.8B | 45 | HOLD |
| FRNM | Freenome, Inc. | $1.2B | 11 | STRONG SELL |
| WGS | GeneDx Holdings Corp. | $1.8B | 14 | STRONG SELL |
| ADPT | Adaptive Biotechnologies Corporation | $3.6B | 44 | HOLD |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%